Dr. Gibson is a senior discovery medicine scientist in the Academic Discovery Performance Unit (AcDPU) within Research and Development at GlaxoSmithKline (GSK)  – the  AcDPU  encourages close collaboration between the GSK team and the academic partners on clinical and early stage studies. Dr. Gibson is responsible for leading the early stage development of several GSK compounds and is the lead scientist for the development of GSK962040 for the treatment of gastroparaesis in Parkinson’s disease. Prior to working within the AcDPU, she completed her PhD at Guy’s Hospital at the University of London on the Molecular Genetics of Fanconi’s anaemia. Following a postdoctoral position Dr. Gibson joined GSK and worked in the field of medical genetics with a focus on the genetics of Parkinson’s disease.